Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent.
Smaller coronary arteries are less able to accommodate late loss after percutaneous coronary interventions than larger arteries. The first-generation drug-eluting stents have been shown to have better control of neo-intimal hyperplasia and lower late lumen loss compared with bare-metal stents. However, the reported rates of binary restenosis are still unsatisfactory and small target vessel interventions remain challenging. Recently, a study using a subset of the SPIRIT III trial has demonstrated that the everolimus-eluting stent lowered late lumen loss, rates of binary restenosis and target lesion revascularization compared with the paclitaxel-eluting stent. In this article, we review previous studies evaluating small-vessel interventions and focus on the everolimus-eluting stent in this clinical entity.
Ito
Hiroki
H
St Vincent Heart Center of Indiana, 10590 N. Meridian St, Suite 300, Indianapolis, IN 46290, USA. itohiroki@gmail.com
Hermiller
James B
JB
D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus